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Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are 
relatively new pharmacological agents used to normalize 
glucose level in type 2 diabetes. Recently, GLP-1RAs have 
been approved for the treatment of obesity to reduce 
body weight in non-diabetic patients. The extra-pancre-
atic effects of GLP-1RAs, as well as their molecular mecha-
nism of action, are still poorly understood. Thus this study 
was aimed to verify the hypothesis that the mechanism 
of action of the GLP-1RAs involves mitochondria and 
that GLP-1RAs administration can improve mitochondrial 
functions. For this purpose, preadipocytes CHUBS7 were 
differentiated to mature adipocytes and then stimulated 
with GLP-1RA, exendin-4 at 100 nM for 24 h. Oxygen con-
sumption rates, mitochondrial membrane potential, in-
tracellular ATP (adenosine triphosphate) level, SIRT1 and 
SIRT3 gene expression and the histone deacetylases’ activ-
ity were measured. Exendin-4 was found to uncouple mi-
tochondrial electron transport from ATP synthesis, slightly 
decreasing mitochondrial membrane potential in ma-
ture adipocytes. Routine respiration and uncoupled oxy- 
gen consumption rates were higher in exendin-4 treated 
adipocytes than in the non-treated cells. The ATP level re-
mained unchanged. Exendin-4 enhanced SIRT1 and SIRT3 
genes expression. Histone deacetylases’ activity in the 
nuclear fraction was not affected by exendin-4, although 
the activity of class III histone deacetylases was increased. 
All of the effects on mitochondrial bioenergetics induced 
by exendin-4 were abolished by addition of glucagon-like 
peptide 1 receptor antagonist. In conclusion, exendin-4 
activates the sirtuin pathway and increases energy ex-
penditure in human adipocytes. Our results suggest an-
other mechanism that may be responsible for body 
weight reduction observed in patients using GLP-1RAs.
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INTRODUCTION
Mitochondria are at the center of cellular metabolism 
and not only provide energy for a variety of metabolic 
processes but also are central for the coordination and 
integration of the various pathways defining the cell’s 
metabolic program. It is well established that mitochon-
dria are critically involved in the pathophysiology of 
metabolic disorders, such as obesity and diabetes (Muoio 
& Newgard, 2008). Mitochondrial function also appears 
to be a critical determinant of insulin sensitivity within 
the muscle, liver, and adipose tissue (Szendroedi et al., 
2011).
Incretins, gut-derived hormones, include glucagon-like 
peptide (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP), that are secreted into the circulation at 
low basal levels at a fasting state but increasing rapidly 
and transiently following food ingestion. GLP-1 is re-
leased in response to food, especially glucose, fatty acids, 
proteins and bile salts in the bowel. The biological ef-
fects of GLP-1 principally include stimulation of insu-
lin expression and insulin biosynthesis (Fehmann et al., 
1997). GLP-1 has been also shown to prevent β-cell ap-
optosis in animal models of diabetes (Li et al., 2003) and 
glucolipotoxicity (Buteau et al., 2004). The GLP-1 plasma 
level is decreased and consecutively the insulinotropic 
effect of this incretin is diminished in type 2 diabetes, 
in obesity or after bariatric surgery (Færch et al., 2015). 
GLP-1 is rapidly degraded in vivo by dipeptidyl peptidase 
IV (DPP IV) located in various tissues, on the capillary 
surfaces, as well as present in a soluble form in the cir-
culation, so active GLP-1 (7-36) has a half-life of 2 min.
Short half- life of native GLP-1 has been overcome 
through the use of chemically modified degradation-re-
sistant glucagon-like peptide 1 receptor agonists (GLP-
1RAs) in therapy of type 2 diabetes. GLP-1RAs mimic 
the effects of native GLP-1, which increases insulin se-
cretion, inhibits glucagon secretion, increases satiety and 
slows gastric emptying (Østergaard et al., 2016). The 
most often used GLP-1 receptor agonists, exenatide and 
liraglutide, administered together with oral antihypergly-
cemic agents have been shown to be effective in the 
treatment of type 2 diabetes. Exenatide (exendin-4) is a 
synthetic agonist of the GLP-1 receptor, approved (in 
2005 in the U.S., in 2006 in the E.U.) for the treatment 
of type 2 diabetes (Drucker et al., 2010). Other therapeu-
tic GLP-1RAs, exhibiting  a more prolonged duration of 
action, include liraglutide (approved in the E.U. in 2009), 
lixisenatide (approved in the E.U. in 2013) and  albiglu-
tide (approved in the E.U. in 2014). GLP-1R agonists 
control blood glucose through stimulation of insulin and 
inhibition of glucagon secretion (Drucker, 2006). These 
GLP-1R–related effects are plasma glucose dependent, 
thereby minimizing the risk of hypoglycemia in the ab-
sence of concomitant sulfonylurea therapy (Butler et al., 
2010; Feher et al., 2017). 
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In addition to glycemic control, the observed effect of 
GLP-1RAs is the reduction in body weight in the major-
ity of treated subjects (Wadden et al., 2013; Lundkvist et 
al., 2017; le Roux et al., 2017). This well-documented ef-
fect results partially from reduced appetite (through the 
action on GLP-1 receptors in the hypothalamus) and 
slowed gastric emptying (McAdam-Marx et al., 2016). 
Moreover, an ultrasound study documented that even a 
short course of treatment with exenatide, besides weight 
loss, induces a redistribution of adipose tissue deposits, 
possibly contributing to a better cardiovascular risk pro-
file in patients with type 2 diabetes (Morano et al., 2015). 
After successful trials with GLP-1RAs at a high dose in 
non-diabetic subjects, the incretin mimetic therapy has 
been approved (in the U.S. in 2014, and in March 2015 
in the E.U.) for treatment of obesity to reduce body 
weight in obese non-diabetic patients (Anandhakrishnan 
& Korbonits, 2016). 
Due to the growing interest in incretin therapy, sev-
eral clinical as well as experimental studies are in pro-
gress, although the mechanism of GLP-1RAs action in 
adipose tissue is not yet sufficiently understood (Majum-
dar & Weber, 2010; Chae et al., 2015; Pastel et al., 2016). 
Thus, our study was aimed to verify the hypothesis that 
the GLP-1 RA mechanism of action involves mitochon-
dria and that GLP-1RA administration can improve mi-
tochondrial functions. For this purpose, the influence of 
GLP-1 RA, namely exendin-4,  on mitochondrial bioen-
ergetics was studied in the CHUBS7 human adipocytes. 
MATERIALS AND METHODS
Cell culture. All reagents were purchased from Sig-
ma-Aldrich, unless stated otherwise. Human cell line 
CHUBS7 (Nestle Research Center, Lausanne, Switzer-
land) derived from human subcutaneous adipose tis-
sue, was cultured in a mixture (1:1) of DMEM and F12 
culture media. Cells were plated (at a density of 30×103 
cells/cm2) in DMEM/F12 media supplemented with 
10% fetal calf serum (Gibco, Grand Island, NY, USA). 
At confluence, the cells were incubated in a basal me-
dium, which was serum-free DMEM/F12 medium sup-
plemented with 15 mM NaHCO3, 17 μM D-panthotenic 
acid, 15 mM Hepes and 33 μM biotin, 10 μg/ml trans-
ferrin, 1 nM triiodothyronine, 850 nM insulin, and fresh-
ly added 500 μg/ml fetuin. The ChubS7 cells were dif-
ferentiated into mature adipocytes by adding 1 μM dexa-
methasone and 1 μM rosiglitazone to the basal medium 
for 21 days. Then adipocytes were exposed to GLP-1R 
agonist, exendin-4 (Ex-4) (100 nM) or to Ex-4 along 
with GLP-1R antagonist, exendin-9 (Ex-9) (100 nM), for 
24 hours. 
Cell differentiation assay. The cellular lipid content 
was assessed by lipid staining with Oil Red-O. Cells were 
washed twice with PBS and fixed in 3.7% paraformal-
dehyde (POCH, Gliwice, Poland) in PBS without Mg2+ 
and Ca2+ (Biomed, Lublin, Poland) for 1 hour at room 
temperature. Then, the paraformaldehyde solution was 
removed, cells were washed shortly with double distilled 
H2O and stained with Oil Red-O solution for 1 hour at 
room temperature. For the staining, 0.5 g of Oil Red-O 
was dissolved in 100 ml of isopropanol (POCh, Gliwice, 
Poland). After 1 hour, the Oil Red-O containing medi-
um was removed and the cells were examined by light 
microscopy. 
Oxygen consumption. Mitochondrial respiration as-
say was performed using the high-resolution respirom-
etry system Oxygraph-2k (Oroboros Instruments, Aus-
tria). Live CHUBS7 cells (1×106) were suspended in 
2 ml of basal medium containing 5 mM glucose (control 
cells) or in 2 ml of basal medium containing 5 mM glu-
cose with exendin-4 (Ex-4), exendin-9 (Ex-9) or in a me-
dium containing 25 mM glucose (high glucose control). 
Oxygen sensors were calibrated routinely at air saturation 
and in oxygen depleted media. Oxygen consumption 
was monitored at 37°C in a thermostatically controlled 
chamber. The protocol according to Dunham-Snary  and 
coworkers (2014) was used.
Intracellular ATP content. The intracellular ATP 
content was measured by using the ATPLiteTM lumines-
cence assay (Perkin Elmer, Waltham, MA, USA), accord-
ing to the protocol provided by the manufacturer, and 
the luminescence was measured using a Tecan Genios 
microplate reader (Thermo Fisher). Data were calculated 
using the Magellan software. Protein content was meas-
ured in the samples of cell lysates by Total Protein Kit, 
Micro Lowry, Peterson’s Modification (Sigma). The ATP 
concentration was adjusted for protein content in each 
sample and expressed as nmol ATP/mg of cell protein.
Mitochondrial membrane potential (∆ψm). Changes 
of the ∆ψm were monitored by fluorescent staining of the 
live CHUBS7cells with JC-1 dye. The cells were incu-
bated with 2 mM JC-1 solution  (MitoProbe Assay Kit, 
Invitrogen Life Technologies, Carlsbad CA, USA) in the 
dark for 45 min at 37°C. Then, the cells were washed, 
diluted in PBS and analyzed by flow-cytometry (FACS-
Canto II, BD Biosciences Discovery Labware, Bedford, 
MA, USA) using 488 nm excitation with 530/30 nm 
(FL1, green) and 585/42 nm (FL2, orange) band pass 
emission filters. Fluorescence of 1×104 cells was col-
lected during a single instrument run. The data were 
analyzed using the FacsDIVA software (BD Biosciences 
Discovery Labware, Bedford, MA, USA). In live cells, 
JC-1 exists either as a green-fluorescent monomer at de-
polarized membrane potentials or as an orange-fluores-
cent J-aggregate at hyperpolarized membrane potentials. 
The mitochondrial membrane potential was quantified 
by a ratio of red to green fluorescence intensities gener-
ated by JC-1 staining. This ratio is dependent only on 
the ∆ψm and not on other factors such as mitochondrial 
size, shape, and density.
Relative gene expression. Total RNA was isolated 
from cells using a TRIzol® Plus RNA Purification Sys-
tem (Life Technologies, Carlsbad, CA, USA). The quality 
of RNA was confirmed by analysis on the NanoDrop 
(Thermo Fisher Scientific, Wilmington, DE, USA). One 
microgram of total RNA was reverse transcribed using 
a reverse transcription kit (High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Carlsbad, 
CA, USA) with random primers. Subsequently, cDNA 
was subjected to real-time PCR. Quantitative real-time 
polymerase chain reaction (qPCR) was performed with 
the TaqMan® Gene Expression Assays, according to the 
manufacturer’s protocol using  TaqMan® primers for 
SIRT1 (Hs01009006_m1) and SIRT3 (Hs00953477_m1) 
(Applied Biosystems). As a reference gene, expression of 
18SrRNA was used (Hs03003631_g1) (Applied Biosys-
tems). Amplification was performed using the continu-
ous fluorescence detection system 7900 HT Fast Real 
Time PCR system (Applied Biosystems). Data were ob-
tained in a form of sigmoid amplification plots in which 
fluorescence was plotted against the number of cycles. 
The threshold cycle (CT) served as a measurement of 
the starting template amount in each sample. Expres-
sion ratio was calculated as normalized CT difference 
between the control probe and the sample. 
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Histone deacetylases activity. Nuclear fraction 
was extracted from CHUBS7 cells using Nuclear Ex-
traction Kit according to the protocol supplied by 
the manufacturer (Merck Millipore, Darmstadt, Ger-
many). The protein concentration was determined by 
Total Protein Kit, Micro Lowry, Peterson’s Modifica-
tion (Sigma). Each nuclear extract sample (10 µg) was 
pipetted into four microplate wells, and was run in 
duplicates with and without addition of trichostatin 
A (TSA). Histone deacetylases’ activity was detected 
using colorimetric HDAC Assay Kit (Millipore), ac-
cording to the protocol supplied by the manufactur-
er. Briefly, samples were incubated with HDAC assay 
substrate for 60 minutes at 37°C, allowing deacetyla-
tion of the substrate. Next, the activator solution, 
incubated for 20 minutes at RT, released the p-ni-
troanilide from deacetylated substrate. Colorimetric p-
nitroanilide was measured in a plate reader (Multiscan) 
at 405 nm. The HDAC activity was calculated using 
a standard curve prepared with an assay standard and 
normalized to protein content.
Statistical analysis. All of data were expressed as 
the mean +S.D. from five independent experiments 
measured in triplicate. Calculation of relative gene 
expression was performed using the comparative CT 
method. Statistical significances for comparisons be-
tween treated and control cell samples were deter-
mined by the unpaired t-test using Statistica  10.0 PL 
software.
RESULTS
Cell differentiation
The morphology of cultured CHUBS7 cells and lipid 
droplets formation were observed with the light micros-
copy. After 21 days of culture, the cells were stained 
with Oil Red-O. Large lipid droplets stained red, and 
filled the greater part of the cells (Fig. 1). The staining 
confirmed that preadipocytes differentiated into mature, 
functional adipocytes. 
Oxygen consumption
The protocol for oxygen consumption rate (OCR) 
measurement in the intact cells (Fig. 2) included in se-
quence: (I) a 10-min period of routine respiration (rou-
tine), reflecting the aerobic metabolic activity under cel-
lular routine conditions, (II) oligomycin (final concen-
tration 2 µg/ml) -inhibited respiration (oligo), which is 
caused mainly by compensation for the proton leak after 
inhibition of ATP synthase; (III) FCCP (p-trifluorometh-
oxy carbonyl cyanide phenyl hydrazone) titration (1.5–
3.0 µM), which yields the maximum stimulated respira-
tion, as a measure of electron transport system capacity 
of uncoupled mitochondria; (IV) antimycin A (12 µM) 
and rotenone (3 µM), that inhibit mitochondrial respira-
tory complexes III and I, respectively (Fig. 2).
Basal OCR of control and Ex-4 treated cells did 
not differ significantly. When the non-mitochondrial 
oxygen consumption, measured after full inhibition 
of mitochondrial electron transport chain by antimy-
cin A and rotenone, was subtracted, the routine mito-
chondrial respiration was increased in the Ex-4 treated 
cells (Fig. 3A). Further analysis after inhibition of the 
ATP synthase by oligomycin revealed that exendin-4 
enhanced non-ATP linked OCR, but did not change 
ATP-linked OCR (Fig. 3B). After stimulation of the 
uncoupling of electron transport chain from ATP syn-
tesis in mitochondria by FCCP, the increased maximal 
mitochondrial OCR and  increased reserved capacity 
in Ex-4 treated cells were found (Fig. 3C). The effects 
of exendin-4 on oxygen consumption rates were abol-
ished when exendin-9 was added to the cells.
Intracellular ATP content
The intracellular ATP levels measured by lumino-
metric method were comparable in the exendin-4 
treated cells, exendin-9 treated cells and control adi-
pocytes (Fig. 3D). These results confirm that the ob-
served increased oxygen consumption by mitochon-
dria was not associated with excessive ATP syntesis, 
although the energy homeostasis was maintained.
Figure 1. Human ChubS7 preadipocytes prior to differentiation 
without staining (A) and with Oil Red-O staining (C); andChubS7 
cells after 21 days of differentiation into adipocytes without 
staining (B) and with Oil Red-O staining (D); magnification 200x.
Figure 2. An example of oxygen consumption rate trace (OCR; 
pmol oxygen per minute per 1x106 cells, mean ±S.D. from 5 ex-
periments) of CHUBS7 cells. 
Each line represents oxygen consumption by 1x106 adipocytes. 
Data were digitally recorded using DatLab4 software where oxy-
gen flux was calculated as the negative time derivative of oxy-
gen concentration (Oxygraph-2k, Oroboros Instruments). Com-
pounds were added in the following sequence: oligomycin (2 µg/
ml), FCCP titration (1.5–3.0 µM), antimycine A (12 µM) + rotenone 
(3 µM). Routine-oxygen consumption without any inhibitors.  Con-
trol cells-untreated CHUBS7 cells suspended in basal medium 
containing 4.5 mM glucose; high glucose-untreated CHUBS7 cells 
cultured for the last 24 h and suspended in medium containing 
25 mM glucose; Ex-4-CHUBS7 cells treated with GLP-1R agonist 
exendin-4 (100 nM, 24 h) suspended in basal medium contain-
ing 4.5 mM glucose; Ex-4+Ex-9-CHUBS7 cells treated with GLP-1R 
agonist exendin-4 (100 nM, 24 h)  along with GLP-1R antagonist 
exendin-9 (100 nM, 24 h) suspended in basal medium containing 
4.5 mM glucose. Abbreviations: oligo, oligomycin, inhibitor of ATP 
synthase; FCCP (p-trifluoromethoxy carbonyl cyanide phenyl hy-
drazone), uncoupler stimulating oxygen consumption; AntiA/rot, 
antimycin A and rotenone, inhibitors of mitochondrial respiratory 
complex III and I, respectively.
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Mitochondrial membrane potential (∆ψm)
Mitochondrial membrane potential was measured by 
JC-1 staining. The ratio of red to green fluorescence 
intensities generated by JC-1 staining was reduced by 
17% (n=5, p<0.05) indicating that the mitochondrial 
membrane potential was slightly decreased in the Ex-4 
treated cells when compared to the control. A reduced 
signal from an orange-fluorescent J-aggregate that is as-
sociated with hyperpolarized membrane potentials and 
indicates mild mitochondrial ETC uncoupling, was re-
corded in the Ex-4 treated cells (Fig. 4). 
Gene expression
Exendin-4 was found to up-regulate two genes cod-
ing for sirtiuns (class III histone deacetylase): SIRT1 
coding for sirtuin 1 and SIRT3 coding for sirtuin 3 
(Fig. 5A, B). This effect was abolished when ex-
endin-9 was added to the cells. 
Figure 3. Mitochondrial respiration measured by high resolution respirometry (Oxygraph-2k, Oroboros Instruments) in CHUBS7 con-
trol cells, exendin-4 (100 nM, 24 h) treated cells (Ex-4) and exendin-4 with exendin-9 (100 nM, 24 h) treated cells (Ex-4+Ex-9). 
(A) basal oxygen consumption rate (OCR), non-mitochondrial OCR (after inhibition of mitochondrial electron transport chain by antimy-
cin A and rotenone) and routine mitochondrial OCR. (B) Not-ATP-linked OCR and ATP-linked OCR. ATP-linked OCR was calculated as the 
difference between routine OCR and OCR measured after inhibition of ATP synthase by oligomycin. Non-ATP-linked oxygen consumption 
rate (OCR) was calculated as the difference between routine and ATP-linked OCR. (C) Maximum mitochondrial OCR and reserved capac-
ity. Maximum OCR was determined by subtracting the non-mitochondrial OCR from the maximal reading following addition of FCCP 
(p-trifluoromethoxy carbonyl cyanide phenyl hydrazone). Reserve capacity was calculated by subtracting the routine OCR from the maximal 
oxygen consumption after the addition of FCCP. (D) Intracellular concentration of ATP measured by a luminometric method, normalized 
to protein content in the cell lysate. Data presented as mean +S.D. from 5 experiments; *p<0.05 compared to control, #p<0.05 compared 
to Ex-4+Ex-9 group.
Figure 4. Flow cytometry analysis of mitochondrial membrane 
potential of CHUBS7 adipocytes by JC-1 staining (FACSCanto II, 
Becton Dickinson). 
Reduced signal from an orange-fluorescent J-aggregate in ex-
endin-4 (100 nM, 24 h) treated cells (Ex-4) compared to control 
CHUBS7 cells.
Figure 5. Relative expression of (A) SIRT1 and (B) SIRT3 genes 
measured by real-time RT-PCR (18SrRNA was used as a reference 
gene); (C) histone deacetylases’ (HDAC) activity measured by 
colorimetric HDAC Assay Kit (Millipore) in nuclear extracts (10 
µg) in CHUBS7 control cells, exendin-4 (100 nM, 24 h) treated 
cells (Ex-4) and exendin-4 with exendin-9 (100 nM, 24 h) treated 
cells (Ex-4+Ex-9). Data presented as mean +S.D. from 5 experi-
ments; *p<0.05 compared to control, #p<0.05 compared to Ex-
4+Ex-9 group.
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Histone deacetylases’ activity
There were no significant differences between the 
exendin-4 treated and untreated adipocytes in the total 
activity of histone deacetylases measured in the nuclear 
extracts (Fig. 5C). Nevertheless, when the trichostatin A, 
an inhibitor of class I HDAC and class II HDAC, was 
added to the nuclear samples, the activity of trichosta-
tin A insensitive HDAC was enhanced in the exendin-4 
treated adipocytes when compared to the control adipo-
cytes. This indirectly indicates an increased activity of 
class III histone deacetylases, i.e. the sirtuins (1-7). 
DISCUSSION
The effect of GLP-1 receptor signaling in central 
nervous system on stimulation of brown adipose tissue 
thermogenesis through adrenergic neurons in rodents is 
well documented, but these results do not exclude the 
possibility of direct influence of GLP-1 on adipocyte 
browning (Lockie et al., 2012; Beiroa et al., 2014). While 
some reports from the rodent studies confirm this hy-
pothesis (Mostafa et al., 2015; Xu et al., 2016), other re-
ports suggest that increased BAT thermogenesis did not 
play a significant role in the food intake-independent 
body weight lowering effect of GLP-1RAs (Heppner et 
al., 2015; Chae et al. 2015). 
A few studies had  indicated direct influence of 
exendin-4 on mitochondrial function. Recently, a 
GLP-1RA (liraglutide) specific reduction of lipid content 
in the liver was reported, along with a decreased expres-
sion of major elements involved in lipogenesis, peroxi-
somal β-oxidation and lipid flux (Decara et al., 2016). In 
the INS-1 rat pancreatic beta cell line, exendin-4 pre-
vented cytokine induced apoptosis through counter-reg-
ulation of the reduced abundance of electron transport 
chain proteins (Tews et al., 2009). Exendin-4 was also 
found to increase mitochondrial mass (Kang et al., 2015). 
A very recent in vitro study had shown that exendin-4 in-
creases basal and fatty acid stimulated oxygen consump-
tion rate, as well as increased expression of thermo-
genic UCP1 and PPAR-α in differentiated muscle cells 
(Choung et al., 2017). Exendin-4 improved mitochondrial 
function by normalization of citrate synthase activity, 
mitochondrial oxidative phosphorylation and supercom-
plex formation in mice after heart failure, and the effects 
were abolished by GLP-1 antagonist, exendin-9 (Takada 
et al., 2016). Mechanisms by which exendin-4 increases 
cardiomyoblasts survival also involve improvement of 
mitochondrial respiration and suppression of the open-
ing of mitochondrial permeability transition pore (DeNi-
cola et al., 2014). 
In our study, exendin-4 stimulated the mitochondrial 
routine and maximal respiration, increased the reserved 
capacity and preserved intracellular ATP level in the 
CHUBS7 adipocytes. It is hypothesized that a reserve 
capacity exists as a compensation mechanism for cells 
when presented with increased workload or as a stress 
response (Cannon & Nedergaard, 2004; Dranka et al., 
2010).  Indeed, uncoupling can be stimulated by either 
high levels of cellular/mitochondrial ROS or by circu-
lating free fatty acids (FFA) (Jarmuszkiewicz et al., 2004; 
Sluse et al., 2006). The effects of exendin-4 on mitochon-
drial membrane potential and mild uncoupling reported 
here, may explain the protective role of GLP-1 (secreted 
physiologically in response to food intake) to adapt to 
the metabolic stress occurring in the postprandial period. 
In the study presented here, exendin-4 up-regulated 
mRNA expression of  SIRT1 and SIRT3, along with the 
bioenergetic effects in the CHUBS7 human adipocyte 
cell line. Sirtuins belong to class III HDAC and thus 
regulate a number of key metabolic enzymes that are 
acetylated, malonylated, or succinylated in mitochondria 
in response to environmental stimuli (Imai et al., 2010; 
Chalkiedaki et al., 2012). Sirtuin1 (Sirt1) extends lifespan 
and is involved in energy metabolism (Frye, 2000). Sir-
tuin 3 (Sirt3), preferentially localized in mitochondria, 
targets enzymes of the respiratory chain, tricarboxylic 
acid cycle, fatty acid β-oxidation and ketogenesis (Hir-
schey et al., 2010; Giralt & Villarroya, 2012). Our results 
for SIRT1 and SIRT 3 expression are in line with  a re-
cent  report that exendin-4 up-regulates adiponectin in 
adipocytes through the Sirt1/Foxo-1 signaling pathway 
(Wang et al., 2017). Similarly, exendin-4 increased lipoly-
sis and fatty acid oxidation by up-regulating SIRT1 ex-
pression and activity in differentiated 3T3-L1 adipocytes 
(Xu et al., 2016). These findings, along with our results, 
give the basis for the hypothesis that GLP-1R agonist 
may promote brown remodeling of WAT in a SIRT1-
dependent manner. Discovery of the involvement of sir-
tuin 1 in the exendin-4 mechanism of action in adipo-
cytes is of great importance in the light of data confirm-
ing depleted sirtuin levels in obesity (Mariani et al., 2016).
In our study, exendin-4 not only up-regulated SIRT1 
and SIRT3 mRNA expression in the CHUBS7 adi-
pocytes, but also increased the class III HDAC activ-
ity, although total HDAC activity was not affected. In 
a recent paper, total HDAC activity was reported to 
be decreased in visceral adipose tissue of obese human 
subjects when compared to normal weight subjects. De-
creased Hdac5 and Hdac6 expression has been shown in 
adipocytes from obese human subjects, as well as from 
obese mice (Bricambert et al., 2016). Activation of sir-
tuins by exendin-4 was also observed in hepatocytes and 
rat retinal cells (Lee et al., 2014; Zeng et al., 2016).  Thus 
the restoration of proper sirtuin activity may be one of 
the mechanisms of pleiotropic effects of GLP-1RAs. 
Recently, there has been observed a growing inter-
est in inducible brown-like adipocytes (“beige”) in white 
adipose tissue depots in response to appropriate stimuli. 
Beige adipocytes have characteristics similar to brown 
adipocytes, in particular the capacity for uncoupled res-
piration. Utilization of nutrients by beige adipocytes im-
proves insulin sensitivity and glucose tolerance, but their 
amount in overweight and obese individuals is reduced 
(Loyd & Obici, 2014). Thus, induction of  browning of 
the white fat represents an attractive potential strategy 
for the management and treatment of obesity and re-
lated complications (Bonet et al., 2013). In this paper, we 
have found that exendin-4 stimulates oxygen consump-
tion and mitochondrial uncoupling in human adipocytes, 
and thus switches mitochondrial bioenergetics towards 
energy expenditure. Detailed studies on human adipose 
tissue are needed to confirm the initial hypothesis that 
exendin-4 could directly induce browning of the white 
adipose tissue in humans. 
This paper makes contribution to the field of study on 
the pleiotropic effects of incretin mimetics. The results 
indicate stimulation of mitochondrial bioenergetics as the 
effect of exendin-4 action in human adipocytes. Enhanced 
expression of sirtuins (1 and 3) may elucidate the mecha-
nism of exendin-4 action in human adipocytes, although 
further studies are needed to investigate the causal rela-
tionship of sirtuin and mitochondrial respiration in this 
model. The results contribute to the understanding of the 
GLP-1RAs  induced weight loss in patients, which results 
not only from a decreased energy intake but also from an 
increased resting energy expenditure.
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